Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus metronomic vinorelbine in elderly advanced non-small cell lung cancer
ChiCTR2000036983Phase 2Recruiting
- Sponsor
- Shulan Health
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and vinorelbine in non-small cell lung cancer (NSCLC), sponsored by Shulan Health. Primary endpoint: Response rate. Started Oct 2020; status: recruiting.
02
Drugs
anlotinibvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000036983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036983.